NASH: GSK agrees with PathAI
GSK announced a partnership with PathAI, an American biotech, specializing in artificial intelligence (AI) for therapeutic research purposes. The agreement concerns the phase IIb trial of GSK4532990, conducted by the British laboratory, for the treatment of patients with NASH and advanced fibrosis. In this study, the role of biotech will be to draw up a histological evaluation of the participants in the trial to measure the effectiveness of the drug candidate, thanks to its AI tools called AIM-NASH. Financial terms of the agreement were not disclosed.
VOS INDICES
source
“We are confident that our new AIM-NASH tool will significantly improve the likelihood of clinical and regulatory success”, said Andy Beck, CEO and co-founder of PathAI. A year ago, the two companies had already signed a first collaboration also focused on NASH, but also oncology.
Strategy: Ipsen prepares for acquisitions
According Bloomberg, the French laboratory is considering several major investments with the aim of getting its hands on innovative drugs. In detail, Ipsen says it is ready to pay more than 2.5 billion euros, according to David Loew, the general manager of the laboratory, who specifies: “We review thousands of companies or compounds per year. (…) Ipsen aims for six to eight transactions per year. » A sustained pace that could accelerate after 2025.
For 2023 alone, the group would be ready to devote an envelope of €1.5 billion, while Ipsen had already made a major acquisition at the start of the year, that of Albireo Pharma for $952 million. The company also plans to increase its R&D spending from 16% of total revenue to around 20% by the end of this year or early 2024. a little more the group’s strategy focused on three therapeutic areas: oncology, rare diseases and neurosciences.
Selected for you
